The Cleveland Clinic Foundation has described 3-β-hydroxysteroid dehydrogenase/δ5-->4-isomerase type 1 (3β-HSD I) inhibitors reported to be useful for the treatment of cancer.

Tempest Therapeutics Inc. has divulged three-prime repair exonuclease 1 (TREX1) inhibitors reported to be useful for the treatment of cancer.

Researchers at Guangzhou Salustier Biosciences Co. Ltd. and Jinan University (Guangdong) have identified selenium-containing heterocyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Biogen Inc. has synthesized non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, autoimmune disease, cardiovascular disorders, fibrosis, inflammatory disorders, liver diseases, pain and neurodegeneration, among others.

Biofront Ltd. disclosed HPK1, FLT3 and AURKA inhibitors reported to be useful for the treatment of cancer.

Researchers at Mayo Foundation for Medical Education and Research (MFMER) and University of Nebraska have described proteolysis targeting chimeric (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a hepatocyte growth factor receptor (HGFR; MET)-targeting moiety through a linker reported to be useful for the cancer.

Alkermes plc has divulged orexin OX2 receptor agonists reported to be useful for the treatment of cataplexy.

Medshine Discovery Inc. has identified heterocyclic substituted pyrimidopyran compounds reported to be useful for the treatment of cancer.

Astrazeneca AB has synthesized fibroblast activation protein-α (FAPα) inhibitors reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH), among others.

Sitryx Therapeutics Ltd. has disclosed nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators reported to be useful for the treatment of inflammatory disorders.